Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use and COVID-19: Time to Change Practice or Keep Gathering Data?

Clin Infect Dis. 2020 Dec 3;71(9):2457-2458. doi: 10.1093/cid/ciaa819.

Authors

Alejandro de Feria¹, Juan M Ortega-Legaspi¹

Affiliation

¹ Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

No abstract available

Keywords: ACEi/ARB; covid-19; hypertension; kidney injury; respiratory failure.

Publication types

Editorial
Comment

MeSH terms

Acute Kidney Injury*
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
COVID-19*
France
Humans
Pandemics
Referral and Consultation
SARS-CoV-2
Time

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors